ANTHEMNSEAnthem Biosciences Limited· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Wed, 12 Nov, 2025 · 18:22 IST

Q2 and H1 FY26 earnings call transcript filed

Management guided margin improvementOrder pipeline disclosedInvestor Communications View source PDFExplain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.3%Reaction day
₹688.25
prior close
₹690.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%+1.6% vs market
Pharmaceuticals & Biotechnology peers, median of 162sector · industry level-0.1%+1.4% vs sector

On the reaction day the stock moved 1.6 pts more than Nifty Midcap 150 and 1.4 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.2
10m
+1.2
15m
+1.9
30m
+2.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.3-0.3+1.6-0.1+1.4
Next day
-1.5-0.3-1.2-0.5-1.0
2d
-3.3+0.4-3.7-0.3-3.0
3d
-4.2-0.2-3.9-1.1-3.1
4d
-6.5+0.1-6.6-1.6-4.9
5d
-5.8+0.1-5.8-1.6-4.2
1w
-8.0-1.4-6.6-3.3-4.7
15d
-4.0-1.2-2.7-3.4-0.5
1m
+1.1-1.2+2.3-4.5+5.6
2m
-8.8-2.1-6.6-7.1-1.7
3m
-0.0-2.3+2.2-9.1+9.1
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences posted H1 FY26 revenue of Rs. 1,090 Cr, EBITDA Rs. 480 Cr (margin 41.4 percent), and PAT Rs. 309 Cr. Net cash Rs. 993 Cr. Commercial molecules grew to 14 from 10 at IPO, with 6 late phase. Management guided margins to upper end of 36 to 37 percent range. Unit-IV greenfield CAPEX of Rs. 1,000 Cr planned to double capacity within two years.

Likely market impact

Strong margin guidance and pipeline expansion reinforce growth visibility, though specialty ingredients dipped as capacity was diverted to busy CRDMO business.